Centessa Pharmaceuticals plc (CNTA)
NASDAQ: CNTA · Real-Time Price · USD
13.23
-1.15 (-8.00%)
At close: Apr 1, 2025, 4:00 PM
13.21
-0.02 (-0.14%)
After-hours: Apr 1, 2025, 6:26 PM EDT
Centessa Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
77
Market Cap
1.76B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CNTA News
- 8 days ago - Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024 - GlobeNewsWire
- 26 days ago - Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting - GlobeNewsWire
- 2 months ago - Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer - GlobeNewsWire
- 3 months ago - Centessa: Shift In Focus With ORX750 Development Continues To Pay Off - Seeking Alpha
- 5 months ago - Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update - GlobeNewsWire
- 6 months ago - Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) - GlobeNewsWire
- 7 months ago - Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares - GlobeNewsWire
- 7 months ago - Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares - GlobeNewsWire